nodes	percent_of_prediction	percent_of_DWPC	metapath
Dihydroergotamine—ABCB1—Lopinavir—acquired immunodeficiency syndrome	0.058	0.0906	CbGbCtD
Dihydroergotamine—ABCB1—Amprenavir—acquired immunodeficiency syndrome	0.0525	0.0819	CbGbCtD
Dihydroergotamine—ABCB1—Indinavir—acquired immunodeficiency syndrome	0.0453	0.0707	CbGbCtD
Dihydroergotamine—ABCB1—Nelfinavir—acquired immunodeficiency syndrome	0.044	0.0687	CbGbCtD
Dihydroergotamine—ABCB1—Saquinavir—acquired immunodeficiency syndrome	0.0398	0.0621	CbGbCtD
Dihydroergotamine—ABCB1—Ritonavir—acquired immunodeficiency syndrome	0.0398	0.0621	CbGbCtD
Dihydroergotamine—ABCB1—Zidovudine—acquired immunodeficiency syndrome	0.0381	0.0595	CbGbCtD
Dihydroergotamine—CYP3A4—Efavirenz—acquired immunodeficiency syndrome	0.037	0.0577	CbGbCtD
Dihydroergotamine—CYP3A4—Nevirapine—acquired immunodeficiency syndrome	0.0348	0.0543	CbGbCtD
Dihydroergotamine—CYP3A4—Lopinavir—acquired immunodeficiency syndrome	0.0348	0.0543	CbGbCtD
Dihydroergotamine—CYP3A4—Delavirdine—acquired immunodeficiency syndrome	0.0314	0.0491	CbGbCtD
Dihydroergotamine—CYP3A4—Amprenavir—acquired immunodeficiency syndrome	0.0314	0.0491	CbGbCtD
Dihydroergotamine—ABCB1—Lamivudine—acquired immunodeficiency syndrome	0.0295	0.0461	CbGbCtD
Dihydroergotamine—CYP3A4—Indinavir—acquired immunodeficiency syndrome	0.0271	0.0424	CbGbCtD
Dihydroergotamine—CYP3A4—Nelfinavir—acquired immunodeficiency syndrome	0.0263	0.0411	CbGbCtD
Dihydroergotamine—CYP3A4—Ritonavir—acquired immunodeficiency syndrome	0.0238	0.0372	CbGbCtD
Dihydroergotamine—CYP3A4—Saquinavir—acquired immunodeficiency syndrome	0.0238	0.0372	CbGbCtD
Dihydroergotamine—CYP3A4—Zidovudine—acquired immunodeficiency syndrome	0.0228	0.0357	CbGbCtD
Dihydroergotamine—HTR1A—blood plasma—acquired immunodeficiency syndrome	0.00204	0.0659	CbGeAlD
Dihydroergotamine—ADRA2A—blood plasma—acquired immunodeficiency syndrome	0.00143	0.0462	CbGeAlD
Dihydroergotamine—HTR6—nervous system—acquired immunodeficiency syndrome	0.00124	0.0403	CbGeAlD
Dihydroergotamine—HTR6—central nervous system—acquired immunodeficiency syndrome	0.0012	0.0388	CbGeAlD
Dihydroergotamine—CYP3A4—blood plasma—acquired immunodeficiency syndrome	0.00112	0.0364	CbGeAlD
Dihydroergotamine—HTR2B—skin of body—acquired immunodeficiency syndrome	0.00109	0.0354	CbGeAlD
Dihydroergotamine—HTR6—brain—acquired immunodeficiency syndrome	0.000951	0.0308	CbGeAlD
Dihydroergotamine—HTR1B—spinal cord—acquired immunodeficiency syndrome	0.00089	0.0288	CbGeAlD
Dihydroergotamine—HTR2B—digestive system—acquired immunodeficiency syndrome	0.000873	0.0283	CbGeAlD
Dihydroergotamine—HTR2B—blood—acquired immunodeficiency syndrome	0.000832	0.0269	CbGeAlD
Dihydroergotamine—ABCB1—blood plasma—acquired immunodeficiency syndrome	0.000795	0.0257	CbGeAlD
Dihydroergotamine—HTR2B—vagina—acquired immunodeficiency syndrome	0.000771	0.025	CbGeAlD
Dihydroergotamine—HTR1B—nervous system—acquired immunodeficiency syndrome	0.00075	0.0243	CbGeAlD
Dihydroergotamine—HTR2B—lung—acquired immunodeficiency syndrome	0.000729	0.0236	CbGeAlD
Dihydroergotamine—HTR1D—nervous system—acquired immunodeficiency syndrome	0.000726	0.0235	CbGeAlD
Dihydroergotamine—HTR1B—central nervous system—acquired immunodeficiency syndrome	0.000722	0.0234	CbGeAlD
Dihydroergotamine—HTR1A—spinal cord—acquired immunodeficiency syndrome	0.000718	0.0233	CbGeAlD
Dihydroergotamine—HTR1D—central nervous system—acquired immunodeficiency syndrome	0.000699	0.0226	CbGeAlD
Dihydroergotamine—HTR2B—nervous system—acquired immunodeficiency syndrome	0.000675	0.0219	CbGeAlD
Dihydroergotamine—HTR2B—central nervous system—acquired immunodeficiency syndrome	0.00065	0.0211	CbGeAlD
Dihydroergotamine—HTR1A—nervous system—acquired immunodeficiency syndrome	0.000605	0.0196	CbGeAlD
Dihydroergotamine—HTR1A—central nervous system—acquired immunodeficiency syndrome	0.000583	0.0189	CbGeAlD
Dihydroergotamine—HTR1B—brain—acquired immunodeficiency syndrome	0.000573	0.0186	CbGeAlD
Dihydroergotamine—HTR1D—brain—acquired immunodeficiency syndrome	0.000555	0.018	CbGeAlD
Dihydroergotamine—ADRA2A—blood—acquired immunodeficiency syndrome	0.000523	0.0169	CbGeAlD
Dihydroergotamine—HTR2B—brain—acquired immunodeficiency syndrome	0.000516	0.0167	CbGeAlD
Dihydroergotamine—ADRA2A—spinal cord—acquired immunodeficiency syndrome	0.000503	0.0163	CbGeAlD
Dihydroergotamine—HTR2B—lymph node—acquired immunodeficiency syndrome	0.000499	0.0162	CbGeAlD
Dihydroergotamine—ADRA2A—vagina—acquired immunodeficiency syndrome	0.000484	0.0157	CbGeAlD
Dihydroergotamine—HTR1A—brain—acquired immunodeficiency syndrome	0.000463	0.015	CbGeAlD
Dihydroergotamine—ADRA2A—lung—acquired immunodeficiency syndrome	0.000458	0.0148	CbGeAlD
Dihydroergotamine—ABCB1—retina—acquired immunodeficiency syndrome	0.000435	0.0141	CbGeAlD
Dihydroergotamine—CYP3A4—digestive system—acquired immunodeficiency syndrome	0.000432	0.014	CbGeAlD
Dihydroergotamine—ADRA2A—nervous system—acquired immunodeficiency syndrome	0.000424	0.0137	CbGeAlD
Dihydroergotamine—CYP3A4—blood—acquired immunodeficiency syndrome	0.000411	0.0133	CbGeAlD
Dihydroergotamine—ADRA2A—central nervous system—acquired immunodeficiency syndrome	0.000408	0.0132	CbGeAlD
Dihydroergotamine—CYP3A4—nervous system—acquired immunodeficiency syndrome	0.000334	0.0108	CbGeAlD
Dihydroergotamine—ADRA2A—brain—acquired immunodeficiency syndrome	0.000324	0.0105	CbGeAlD
Dihydroergotamine—CYP3A4—central nervous system—acquired immunodeficiency syndrome	0.000321	0.0104	CbGeAlD
Dihydroergotamine—Musculoskeletal discomfort—Indinavir—acquired immunodeficiency syndrome	0.000319	0.00106	CcSEcCtD
Dihydroergotamine—Pruritus—Nevirapine—acquired immunodeficiency syndrome	0.000317	0.00105	CcSEcCtD
Dihydroergotamine—Vomiting—Didanosine—acquired immunodeficiency syndrome	0.000317	0.00105	CcSEcCtD
Dihydroergotamine—Agitation—Saquinavir—acquired immunodeficiency syndrome	0.000317	0.00105	CcSEcCtD
Dihydroergotamine—Palpitations—Ritonavir—acquired immunodeficiency syndrome	0.000316	0.00105	CcSEcCtD
Dihydroergotamine—Insomnia—Indinavir—acquired immunodeficiency syndrome	0.000316	0.00105	CcSEcCtD
Dihydroergotamine—Muscle spasms—Lamivudine—acquired immunodeficiency syndrome	0.000316	0.00105	CcSEcCtD
Dihydroergotamine—Oedema—Delavirdine—acquired immunodeficiency syndrome	0.000316	0.00105	CcSEcCtD
Dihydroergotamine—Anorexia—Efavirenz—acquired immunodeficiency syndrome	0.000315	0.00104	CcSEcCtD
Dihydroergotamine—Rash—Didanosine—acquired immunodeficiency syndrome	0.000314	0.00104	CcSEcCtD
Dihydroergotamine—Paraesthesia—Indinavir—acquired immunodeficiency syndrome	0.000314	0.00104	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Abacavir—acquired immunodeficiency syndrome	0.000314	0.00104	CcSEcCtD
Dihydroergotamine—Dermatitis—Didanosine—acquired immunodeficiency syndrome	0.000314	0.00104	CcSEcCtD
Dihydroergotamine—ADRA2A—lymph node—acquired immunodeficiency syndrome	0.000313	0.0101	CbGeAlD
Dihydroergotamine—Headache—Didanosine—acquired immunodeficiency syndrome	0.000312	0.00103	CcSEcCtD
Dihydroergotamine—Dyspnoea—Indinavir—acquired immunodeficiency syndrome	0.000312	0.00103	CcSEcCtD
Dihydroergotamine—Asthenia—Nelfinavir—acquired immunodeficiency syndrome	0.000311	0.00103	CcSEcCtD
Dihydroergotamine—Shock—Delavirdine—acquired immunodeficiency syndrome	0.000311	0.00103	CcSEcCtD
Dihydroergotamine—Malaise—Saquinavir—acquired immunodeficiency syndrome	0.000311	0.00103	CcSEcCtD
Dihydroergotamine—Somnolence—Indinavir—acquired immunodeficiency syndrome	0.000311	0.00103	CcSEcCtD
Dihydroergotamine—Asthenia—Stavudine—acquired immunodeficiency syndrome	0.00031	0.00103	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Zidovudine—acquired immunodeficiency syndrome	0.00031	0.00103	CcSEcCtD
Dihydroergotamine—Vertigo—Saquinavir—acquired immunodeficiency syndrome	0.00031	0.00103	CcSEcCtD
Dihydroergotamine—ABCB1—lymphoid tissue—acquired immunodeficiency syndrome	0.000309	0.01	CbGeAlD
Dihydroergotamine—Hypertension—Ritonavir—acquired immunodeficiency syndrome	0.000309	0.00103	CcSEcCtD
Dihydroergotamine—Tachycardia—Delavirdine—acquired immunodeficiency syndrome	0.000308	0.00102	CcSEcCtD
Dihydroergotamine—Tremor—Lamivudine—acquired immunodeficiency syndrome	0.000308	0.00102	CcSEcCtD
Dihydroergotamine—Dyspepsia—Indinavir—acquired immunodeficiency syndrome	0.000308	0.00102	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Zidovudine—acquired immunodeficiency syndrome	0.000307	0.00102	CcSEcCtD
Dihydroergotamine—Pruritus—Nelfinavir—acquired immunodeficiency syndrome	0.000307	0.00102	CcSEcCtD
Dihydroergotamine—Diarrhoea—Nevirapine—acquired immunodeficiency syndrome	0.000306	0.00102	CcSEcCtD
Dihydroergotamine—Pruritus—Stavudine—acquired immunodeficiency syndrome	0.000306	0.00101	CcSEcCtD
Dihydroergotamine—Asthenia—Abacavir—acquired immunodeficiency syndrome	0.000306	0.00101	CcSEcCtD
Dihydroergotamine—ABCB1—digestive system—acquired immunodeficiency syndrome	0.000306	0.0099	CbGeAlD
Dihydroergotamine—Hyperhidrosis—Delavirdine—acquired immunodeficiency syndrome	0.000306	0.00101	CcSEcCtD
Dihydroergotamine—Ill-defined disorder—Lamivudine—acquired immunodeficiency syndrome	0.000305	0.00101	CcSEcCtD
Dihydroergotamine—Arthralgia—Ritonavir—acquired immunodeficiency syndrome	0.000305	0.00101	CcSEcCtD
Dihydroergotamine—Myalgia—Ritonavir—acquired immunodeficiency syndrome	0.000305	0.00101	CcSEcCtD
Dihydroergotamine—Decreased appetite—Indinavir—acquired immunodeficiency syndrome	0.000304	0.00101	CcSEcCtD
Dihydroergotamine—Anxiety—Ritonavir—acquired immunodeficiency syndrome	0.000304	0.00101	CcSEcCtD
Dihydroergotamine—Pruritus—Abacavir—acquired immunodeficiency syndrome	0.000301	0.000999	CcSEcCtD
Dihydroergotamine—Fatigue—Indinavir—acquired immunodeficiency syndrome	0.000301	0.000999	CcSEcCtD
Dihydroergotamine—Anorexia—Delavirdine—acquired immunodeficiency syndrome	0.000301	0.000999	CcSEcCtD
Dihydroergotamine—Discomfort—Ritonavir—acquired immunodeficiency syndrome	0.000301	0.000999	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Efavirenz—acquired immunodeficiency syndrome	0.000301	0.000998	CcSEcCtD
Dihydroergotamine—Pain—Indinavir—acquired immunodeficiency syndrome	0.000299	0.000991	CcSEcCtD
Dihydroergotamine—Insomnia—Efavirenz—acquired immunodeficiency syndrome	0.000299	0.000991	CcSEcCtD
Dihydroergotamine—Urticaria—Zidovudine—acquired immunodeficiency syndrome	0.000299	0.00099	CcSEcCtD
Dihydroergotamine—Dry mouth—Ritonavir—acquired immunodeficiency syndrome	0.000298	0.000989	CcSEcCtD
Dihydroergotamine—Hypertension—Saquinavir—acquired immunodeficiency syndrome	0.000298	0.000987	CcSEcCtD
Dihydroergotamine—Abdominal pain—Zidovudine—acquired immunodeficiency syndrome	0.000297	0.000985	CcSEcCtD
Dihydroergotamine—Body temperature increased—Zidovudine—acquired immunodeficiency syndrome	0.000297	0.000985	CcSEcCtD
Dihydroergotamine—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	0.000297	0.000984	CcSEcCtD
Dihydroergotamine—Paraesthesia—Efavirenz—acquired immunodeficiency syndrome	0.000297	0.000983	CcSEcCtD
Dihydroergotamine—Malaise—Lamivudine—acquired immunodeficiency syndrome	0.000297	0.000983	CcSEcCtD
Dihydroergotamine—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	0.000296	0.000981	CcSEcCtD
Dihydroergotamine—Nausea—Didanosine—acquired immunodeficiency syndrome	0.000296	0.000981	CcSEcCtD
Dihydroergotamine—Vertigo—Lamivudine—acquired immunodeficiency syndrome	0.000295	0.000979	CcSEcCtD
Dihydroergotamine—Hypotension—Delavirdine—acquired immunodeficiency syndrome	0.000295	0.000979	CcSEcCtD
Dihydroergotamine—Confusional state—Ritonavir—acquired immunodeficiency syndrome	0.000295	0.000977	CcSEcCtD
Dihydroergotamine—Dyspnoea—Efavirenz—acquired immunodeficiency syndrome	0.000294	0.000976	CcSEcCtD
Dihydroergotamine—Somnolence—Efavirenz—acquired immunodeficiency syndrome	0.000294	0.000974	CcSEcCtD
Dihydroergotamine—Myalgia—Saquinavir—acquired immunodeficiency syndrome	0.000293	0.000973	CcSEcCtD
Dihydroergotamine—Arthralgia—Saquinavir—acquired immunodeficiency syndrome	0.000293	0.000973	CcSEcCtD
Dihydroergotamine—Anxiety—Saquinavir—acquired immunodeficiency syndrome	0.000292	0.00097	CcSEcCtD
Dihydroergotamine—Oedema—Ritonavir—acquired immunodeficiency syndrome	0.000292	0.000969	CcSEcCtD
Dihydroergotamine—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	0.000292	0.000967	CcSEcCtD
Dihydroergotamine—ABCB1—blood—acquired immunodeficiency syndrome	0.000291	0.00943	CbGeAlD
Dihydroergotamine—Dyspepsia—Efavirenz—acquired immunodeficiency syndrome	0.000291	0.000964	CcSEcCtD
Dihydroergotamine—Discomfort—Saquinavir—acquired immunodeficiency syndrome	0.00029	0.000961	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Indinavir—acquired immunodeficiency syndrome	0.000288	0.000955	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Delavirdine—acquired immunodeficiency syndrome	0.000288	0.000955	CcSEcCtD
Dihydroergotamine—Shock—Ritonavir—acquired immunodeficiency syndrome	0.000288	0.000953	CcSEcCtD
Dihydroergotamine—Decreased appetite—Efavirenz—acquired immunodeficiency syndrome	0.000287	0.000952	CcSEcCtD
Dihydroergotamine—Dry mouth—Saquinavir—acquired immunodeficiency syndrome	0.000287	0.000952	CcSEcCtD
Dihydroergotamine—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	0.000287	0.000951	CcSEcCtD
Dihydroergotamine—Dizziness—Stavudine—acquired immunodeficiency syndrome	0.000286	0.000948	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Indinavir—acquired immunodeficiency syndrome	0.000286	0.000948	CcSEcCtD
Dihydroergotamine—Insomnia—Delavirdine—acquired immunodeficiency syndrome	0.000286	0.000948	CcSEcCtD
Dihydroergotamine—Tachycardia—Ritonavir—acquired immunodeficiency syndrome	0.000285	0.000946	CcSEcCtD
Dihydroergotamine—Vomiting—Nevirapine—acquired immunodeficiency syndrome	0.000285	0.000944	CcSEcCtD
Dihydroergotamine—Fatigue—Efavirenz—acquired immunodeficiency syndrome	0.000285	0.000944	CcSEcCtD
Dihydroergotamine—Paraesthesia—Delavirdine—acquired immunodeficiency syndrome	0.000284	0.000941	CcSEcCtD
Dihydroergotamine—Confusional state—Saquinavir—acquired immunodeficiency syndrome	0.000284	0.00094	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Ritonavir—acquired immunodeficiency syndrome	0.000283	0.000937	CcSEcCtD
Dihydroergotamine—Pain—Efavirenz—acquired immunodeficiency syndrome	0.000282	0.000937	CcSEcCtD
Dihydroergotamine—Rash—Nevirapine—acquired immunodeficiency syndrome	0.000282	0.000936	CcSEcCtD
Dihydroergotamine—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	0.000282	0.000936	CcSEcCtD
Dihydroergotamine—Dyspnoea—Delavirdine—acquired immunodeficiency syndrome	0.000282	0.000934	CcSEcCtD
Dihydroergotamine—Dizziness—Abacavir—acquired immunodeficiency syndrome	0.000282	0.000934	CcSEcCtD
Dihydroergotamine—ABCB1—bone marrow—acquired immunodeficiency syndrome	0.000282	0.00912	CbGeAlD
Dihydroergotamine—Oedema—Saquinavir—acquired immunodeficiency syndrome	0.000281	0.000933	CcSEcCtD
Dihydroergotamine—Somnolence—Delavirdine—acquired immunodeficiency syndrome	0.000281	0.000932	CcSEcCtD
Dihydroergotamine—Headache—Nevirapine—acquired immunodeficiency syndrome	0.000281	0.00093	CcSEcCtD
Dihydroergotamine—ABCB1—spinal cord—acquired immunodeficiency syndrome	0.000281	0.00908	CbGeAlD
Dihydroergotamine—Arthralgia—Lamivudine—acquired immunodeficiency syndrome	0.00028	0.000928	CcSEcCtD
Dihydroergotamine—Myalgia—Lamivudine—acquired immunodeficiency syndrome	0.00028	0.000928	CcSEcCtD
Dihydroergotamine—Anxiety—Lamivudine—acquired immunodeficiency syndrome	0.000279	0.000925	CcSEcCtD
Dihydroergotamine—Anorexia—Ritonavir—acquired immunodeficiency syndrome	0.000279	0.000924	CcSEcCtD
Dihydroergotamine—Dyspepsia—Delavirdine—acquired immunodeficiency syndrome	0.000278	0.000922	CcSEcCtD
Dihydroergotamine—Urticaria—Indinavir—acquired immunodeficiency syndrome	0.000278	0.000921	CcSEcCtD
Dihydroergotamine—Shock—Saquinavir—acquired immunodeficiency syndrome	0.000277	0.000918	CcSEcCtD
Dihydroergotamine—Discomfort—Lamivudine—acquired immunodeficiency syndrome	0.000277	0.000917	CcSEcCtD
Dihydroergotamine—Body temperature increased—Indinavir—acquired immunodeficiency syndrome	0.000276	0.000916	CcSEcCtD
Dihydroergotamine—Abdominal pain—Indinavir—acquired immunodeficiency syndrome	0.000276	0.000916	CcSEcCtD
Dihydroergotamine—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	0.000276	0.000915	CcSEcCtD
Dihydroergotamine—Vomiting—Stavudine—acquired immunodeficiency syndrome	0.000275	0.000912	CcSEcCtD
Dihydroergotamine—Decreased appetite—Delavirdine—acquired immunodeficiency syndrome	0.000275	0.000911	CcSEcCtD
Dihydroergotamine—Dry mouth—Lamivudine—acquired immunodeficiency syndrome	0.000274	0.000908	CcSEcCtD
Dihydroergotamine—Rash—Nelfinavir—acquired immunodeficiency syndrome	0.000274	0.000907	CcSEcCtD
Dihydroergotamine—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	0.000273	0.000906	CcSEcCtD
Dihydroergotamine—Hypotension—Ritonavir—acquired immunodeficiency syndrome	0.000273	0.000905	CcSEcCtD
Dihydroergotamine—Rash—Stavudine—acquired immunodeficiency syndrome	0.000273	0.000904	CcSEcCtD
Dihydroergotamine—Fatigue—Delavirdine—acquired immunodeficiency syndrome	0.000272	0.000903	CcSEcCtD
Dihydroergotamine—Dermatitis—Stavudine—acquired immunodeficiency syndrome	0.000272	0.000903	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Efavirenz—acquired immunodeficiency syndrome	0.000272	0.000902	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Saquinavir—acquired immunodeficiency syndrome	0.000272	0.000902	CcSEcCtD
Dihydroergotamine—Headache—Nelfinavir—acquired immunodeficiency syndrome	0.000272	0.000901	CcSEcCtD
Dihydroergotamine—Headache—Stavudine—acquired immunodeficiency syndrome	0.000271	0.000898	CcSEcCtD
Dihydroergotamine—Vomiting—Abacavir—acquired immunodeficiency syndrome	0.000271	0.000898	CcSEcCtD
Dihydroergotamine—Confusional state—Lamivudine—acquired immunodeficiency syndrome	0.000271	0.000897	CcSEcCtD
Dihydroergotamine—Pain—Delavirdine—acquired immunodeficiency syndrome	0.00027	0.000896	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Efavirenz—acquired immunodeficiency syndrome	0.00027	0.000896	CcSEcCtD
Dihydroergotamine—ABCB1—vagina—acquired immunodeficiency syndrome	0.00027	0.00874	CbGeAlD
Dihydroergotamine—Asthenia—Zidovudine—acquired immunodeficiency syndrome	0.00027	0.000894	CcSEcCtD
Dihydroergotamine—Rash—Abacavir—acquired immunodeficiency syndrome	0.000269	0.000891	CcSEcCtD
Dihydroergotamine—Dermatitis—Abacavir—acquired immunodeficiency syndrome	0.000268	0.00089	CcSEcCtD
Dihydroergotamine—Oedema—Lamivudine—acquired immunodeficiency syndrome	0.000268	0.00089	CcSEcCtD
Dihydroergotamine—Anorexia—Saquinavir—acquired immunodeficiency syndrome	0.000268	0.000889	CcSEcCtD
Dihydroergotamine—Headache—Abacavir—acquired immunodeficiency syndrome	0.000267	0.000885	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Ritonavir—acquired immunodeficiency syndrome	0.000266	0.000883	CcSEcCtD
Dihydroergotamine—Nausea—Nevirapine—acquired immunodeficiency syndrome	0.000266	0.000882	CcSEcCtD
Dihydroergotamine—Pruritus—Zidovudine—acquired immunodeficiency syndrome	0.000266	0.000882	CcSEcCtD
Dihydroergotamine—Insomnia—Ritonavir—acquired immunodeficiency syndrome	0.000264	0.000876	CcSEcCtD
Dihydroergotamine—Shock—Lamivudine—acquired immunodeficiency syndrome	0.000264	0.000875	CcSEcCtD
Dihydroergotamine—Hypotension—Saquinavir—acquired immunodeficiency syndrome	0.000263	0.000872	CcSEcCtD
Dihydroergotamine—Paraesthesia—Ritonavir—acquired immunodeficiency syndrome	0.000262	0.00087	CcSEcCtD
Dihydroergotamine—Urticaria—Efavirenz—acquired immunodeficiency syndrome	0.000262	0.00087	CcSEcCtD
Dihydroergotamine—Abdominal pain—Efavirenz—acquired immunodeficiency syndrome	0.000261	0.000866	CcSEcCtD
Dihydroergotamine—Body temperature increased—Efavirenz—acquired immunodeficiency syndrome	0.000261	0.000866	CcSEcCtD
Dihydroergotamine—Dyspnoea—Ritonavir—acquired immunodeficiency syndrome	0.000261	0.000864	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Delavirdine—acquired immunodeficiency syndrome	0.00026	0.000863	CcSEcCtD
Dihydroergotamine—Somnolence—Ritonavir—acquired immunodeficiency syndrome	0.00026	0.000861	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Lamivudine—acquired immunodeficiency syndrome	0.000259	0.00086	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Delavirdine—acquired immunodeficiency syndrome	0.000258	0.000857	CcSEcCtD
Dihydroergotamine—Nausea—Nelfinavir—acquired immunodeficiency syndrome	0.000258	0.000854	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	0.000258	0.000854	CcSEcCtD
Dihydroergotamine—Dyspepsia—Ritonavir—acquired immunodeficiency syndrome	0.000257	0.000853	CcSEcCtD
Dihydroergotamine—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	0.000257	0.000853	CcSEcCtD
Dihydroergotamine—Nausea—Stavudine—acquired immunodeficiency syndrome	0.000257	0.000852	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Saquinavir—acquired immunodeficiency syndrome	0.000256	0.00085	CcSEcCtD
Dihydroergotamine—Anorexia—Lamivudine—acquired immunodeficiency syndrome	0.000256	0.000848	CcSEcCtD
Dihydroergotamine—ABCB1—lung—acquired immunodeficiency syndrome	0.000255	0.00827	CbGeAlD
Dihydroergotamine—Insomnia—Saquinavir—acquired immunodeficiency syndrome	0.000254	0.000844	CcSEcCtD
Dihydroergotamine—Decreased appetite—Ritonavir—acquired immunodeficiency syndrome	0.000254	0.000842	CcSEcCtD
Dihydroergotamine—Nausea—Abacavir—acquired immunodeficiency syndrome	0.000253	0.000839	CcSEcCtD
Dihydroergotamine—Paraesthesia—Saquinavir—acquired immunodeficiency syndrome	0.000253	0.000837	CcSEcCtD
Dihydroergotamine—Fatigue—Ritonavir—acquired immunodeficiency syndrome	0.000252	0.000835	CcSEcCtD
Dihydroergotamine—Urticaria—Delavirdine—acquired immunodeficiency syndrome	0.000251	0.000832	CcSEcCtD
Dihydroergotamine—Asthenia—Indinavir—acquired immunodeficiency syndrome	0.000251	0.000832	CcSEcCtD
Dihydroergotamine—Dyspnoea—Saquinavir—acquired immunodeficiency syndrome	0.000251	0.000832	CcSEcCtD
Dihydroergotamine—Hypotension—Lamivudine—acquired immunodeficiency syndrome	0.000251	0.000831	CcSEcCtD
Dihydroergotamine—Somnolence—Saquinavir—acquired immunodeficiency syndrome	0.00025	0.000829	CcSEcCtD
Dihydroergotamine—Pain—Ritonavir—acquired immunodeficiency syndrome	0.00025	0.000829	CcSEcCtD
Dihydroergotamine—Abdominal pain—Delavirdine—acquired immunodeficiency syndrome	0.00025	0.000828	CcSEcCtD
Dihydroergotamine—Body temperature increased—Delavirdine—acquired immunodeficiency syndrome	0.00025	0.000828	CcSEcCtD
Dihydroergotamine—Dizziness—Zidovudine—acquired immunodeficiency syndrome	0.000249	0.000824	CcSEcCtD
Dihydroergotamine—Dyspepsia—Saquinavir—acquired immunodeficiency syndrome	0.000248	0.000821	CcSEcCtD
Dihydroergotamine—Pruritus—Indinavir—acquired immunodeficiency syndrome	0.000247	0.00082	CcSEcCtD
Dihydroergotamine—Decreased appetite—Saquinavir—acquired immunodeficiency syndrome	0.000245	0.000811	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Lamivudine—acquired immunodeficiency syndrome	0.000244	0.000811	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	0.000243	0.000807	CcSEcCtD
Dihydroergotamine—Insomnia—Lamivudine—acquired immunodeficiency syndrome	0.000243	0.000805	CcSEcCtD
Dihydroergotamine—Fatigue—Saquinavir—acquired immunodeficiency syndrome	0.000243	0.000804	CcSEcCtD
Dihydroergotamine—Paraesthesia—Lamivudine—acquired immunodeficiency syndrome	0.000241	0.000799	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Ritonavir—acquired immunodeficiency syndrome	0.000241	0.000799	CcSEcCtD
Dihydroergotamine—Pain—Saquinavir—acquired immunodeficiency syndrome	0.000241	0.000798	CcSEcCtD
Dihydroergotamine—Dyspnoea—Lamivudine—acquired immunodeficiency syndrome	0.000239	0.000793	CcSEcCtD
Dihydroergotamine—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	0.000239	0.000793	CcSEcCtD
Dihydroergotamine—Vomiting—Zidovudine—acquired immunodeficiency syndrome	0.000239	0.000792	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Ritonavir—acquired immunodeficiency syndrome	0.000239	0.000792	CcSEcCtD
Dihydroergotamine—Somnolence—Lamivudine—acquired immunodeficiency syndrome	0.000239	0.000791	CcSEcCtD
Dihydroergotamine—Rash—Zidovudine—acquired immunodeficiency syndrome	0.000237	0.000786	CcSEcCtD
Dihydroergotamine—Asthenia—Efavirenz—acquired immunodeficiency syndrome	0.000237	0.000786	CcSEcCtD
Dihydroergotamine—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	0.000237	0.000785	CcSEcCtD
Dihydroergotamine—ABCB1—nervous system—acquired immunodeficiency syndrome	0.000236	0.00765	CbGeAlD
Dihydroergotamine—Dyspepsia—Lamivudine—acquired immunodeficiency syndrome	0.000236	0.000783	CcSEcCtD
Dihydroergotamine—Headache—Zidovudine—acquired immunodeficiency syndrome	0.000235	0.000781	CcSEcCtD
Dihydroergotamine—Pruritus—Efavirenz—acquired immunodeficiency syndrome	0.000234	0.000775	CcSEcCtD
Dihydroergotamine—Decreased appetite—Lamivudine—acquired immunodeficiency syndrome	0.000233	0.000773	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	0.000233	0.000772	CcSEcCtD
Dihydroergotamine—Urticaria—Ritonavir—acquired immunodeficiency syndrome	0.000232	0.00077	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Saquinavir—acquired immunodeficiency syndrome	0.000232	0.000769	CcSEcCtD
Dihydroergotamine—Fatigue—Lamivudine—acquired immunodeficiency syndrome	0.000231	0.000767	CcSEcCtD
Dihydroergotamine—Dizziness—Indinavir—acquired immunodeficiency syndrome	0.000231	0.000767	CcSEcCtD
Dihydroergotamine—Abdominal pain—Ritonavir—acquired immunodeficiency syndrome	0.000231	0.000766	CcSEcCtD
Dihydroergotamine—Body temperature increased—Ritonavir—acquired immunodeficiency syndrome	0.000231	0.000766	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Saquinavir—acquired immunodeficiency syndrome	0.00023	0.000763	CcSEcCtD
Dihydroergotamine—Pain—Lamivudine—acquired immunodeficiency syndrome	0.000229	0.000761	CcSEcCtD
Dihydroergotamine—ABCB1—central nervous system—acquired immunodeficiency syndrome	0.000228	0.00737	CbGeAlD
Dihydroergotamine—Asthenia—Delavirdine—acquired immunodeficiency syndrome	0.000227	0.000752	CcSEcCtD
Dihydroergotamine—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	0.000226	0.000749	CcSEcCtD
Dihydroergotamine—Pruritus—Delavirdine—acquired immunodeficiency syndrome	0.000224	0.000741	CcSEcCtD
Dihydroergotamine—Urticaria—Saquinavir—acquired immunodeficiency syndrome	0.000223	0.000741	CcSEcCtD
Dihydroergotamine—Nausea—Zidovudine—acquired immunodeficiency syndrome	0.000223	0.00074	CcSEcCtD
Dihydroergotamine—Body temperature increased—Saquinavir—acquired immunodeficiency syndrome	0.000222	0.000737	CcSEcCtD
Dihydroergotamine—Abdominal pain—Saquinavir—acquired immunodeficiency syndrome	0.000222	0.000737	CcSEcCtD
Dihydroergotamine—Vomiting—Indinavir—acquired immunodeficiency syndrome	0.000222	0.000737	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Lamivudine—acquired immunodeficiency syndrome	0.000221	0.000733	CcSEcCtD
Dihydroergotamine—Rash—Indinavir—acquired immunodeficiency syndrome	0.00022	0.000731	CcSEcCtD
Dihydroergotamine—Dermatitis—Indinavir—acquired immunodeficiency syndrome	0.00022	0.00073	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Lamivudine—acquired immunodeficiency syndrome	0.000219	0.000728	CcSEcCtD
Dihydroergotamine—Headache—Indinavir—acquired immunodeficiency syndrome	0.000219	0.000726	CcSEcCtD
Dihydroergotamine—Dizziness—Efavirenz—acquired immunodeficiency syndrome	0.000218	0.000724	CcSEcCtD
Dihydroergotamine—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	0.000216	0.000717	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	0.000215	0.000714	CcSEcCtD
Dihydroergotamine—Urticaria—Lamivudine—acquired immunodeficiency syndrome	0.000213	0.000707	CcSEcCtD
Dihydroergotamine—Abdominal pain—Lamivudine—acquired immunodeficiency syndrome	0.000212	0.000703	CcSEcCtD
Dihydroergotamine—Body temperature increased—Lamivudine—acquired immunodeficiency syndrome	0.000212	0.000703	CcSEcCtD
Dihydroergotamine—Vomiting—Efavirenz—acquired immunodeficiency syndrome	0.00021	0.000696	CcSEcCtD
Dihydroergotamine—Asthenia—Ritonavir—acquired immunodeficiency syndrome	0.00021	0.000695	CcSEcCtD
Dihydroergotamine—Dizziness—Delavirdine—acquired immunodeficiency syndrome	0.000209	0.000693	CcSEcCtD
Dihydroergotamine—Rash—Efavirenz—acquired immunodeficiency syndrome	0.000208	0.000691	CcSEcCtD
Dihydroergotamine—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	0.000208	0.00069	CcSEcCtD
Dihydroergotamine—Nausea—Indinavir—acquired immunodeficiency syndrome	0.000208	0.000689	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	0.000207	0.000687	CcSEcCtD
Dihydroergotamine—Headache—Efavirenz—acquired immunodeficiency syndrome	0.000207	0.000686	CcSEcCtD
Dihydroergotamine—Pruritus—Ritonavir—acquired immunodeficiency syndrome	0.000207	0.000686	CcSEcCtD
Dihydroergotamine—Asthenia—Saquinavir—acquired immunodeficiency syndrome	0.000202	0.000669	CcSEcCtD
Dihydroergotamine—Vomiting—Delavirdine—acquired immunodeficiency syndrome	0.000201	0.000666	CcSEcCtD
Dihydroergotamine—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	0.0002	0.000663	CcSEcCtD
Dihydroergotamine—Rash—Delavirdine—acquired immunodeficiency syndrome	0.000199	0.000661	CcSEcCtD
Dihydroergotamine—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	0.000199	0.00066	CcSEcCtD
Dihydroergotamine—Pruritus—Saquinavir—acquired immunodeficiency syndrome	0.000199	0.00066	CcSEcCtD
Dihydroergotamine—Headache—Delavirdine—acquired immunodeficiency syndrome	0.000198	0.000656	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	0.000198	0.000656	CcSEcCtD
Dihydroergotamine—Nausea—Efavirenz—acquired immunodeficiency syndrome	0.000196	0.000651	CcSEcCtD
Dihydroergotamine—Dizziness—Ritonavir—acquired immunodeficiency syndrome	0.000193	0.000641	CcSEcCtD
Dihydroergotamine—Asthenia—Lamivudine—acquired immunodeficiency syndrome	0.000193	0.000638	CcSEcCtD
Dihydroergotamine—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	0.000192	0.000638	CcSEcCtD
Dihydroergotamine—Pruritus—Lamivudine—acquired immunodeficiency syndrome	0.00019	0.000629	CcSEcCtD
Dihydroergotamine—Nausea—Delavirdine—acquired immunodeficiency syndrome	0.000188	0.000622	CcSEcCtD
Dihydroergotamine—Dizziness—Saquinavir—acquired immunodeficiency syndrome	0.000186	0.000617	CcSEcCtD
Dihydroergotamine—Vomiting—Ritonavir—acquired immunodeficiency syndrome	0.000186	0.000616	CcSEcCtD
Dihydroergotamine—Rash—Ritonavir—acquired immunodeficiency syndrome	0.000184	0.000611	CcSEcCtD
Dihydroergotamine—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	0.000184	0.00061	CcSEcCtD
Dihydroergotamine—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	0.000184	0.000609	CcSEcCtD
Dihydroergotamine—Headache—Ritonavir—acquired immunodeficiency syndrome	0.000183	0.000607	CcSEcCtD
Dihydroergotamine—ABCB1—brain—acquired immunodeficiency syndrome	0.000181	0.00585	CbGeAlD
Dihydroergotamine—Vomiting—Saquinavir—acquired immunodeficiency syndrome	0.000179	0.000593	CcSEcCtD
Dihydroergotamine—Dizziness—Lamivudine—acquired immunodeficiency syndrome	0.000177	0.000588	CcSEcCtD
Dihydroergotamine—Rash—Saquinavir—acquired immunodeficiency syndrome	0.000177	0.000588	CcSEcCtD
Dihydroergotamine—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	0.000177	0.000588	CcSEcCtD
Dihydroergotamine—Headache—Saquinavir—acquired immunodeficiency syndrome	0.000176	0.000584	CcSEcCtD
Dihydroergotamine—ABCB1—lymph node—acquired immunodeficiency syndrome	0.000175	0.00565	CbGeAlD
Dihydroergotamine—Nausea—Ritonavir—acquired immunodeficiency syndrome	0.000174	0.000576	CcSEcCtD
Dihydroergotamine—Vomiting—Lamivudine—acquired immunodeficiency syndrome	0.000171	0.000566	CcSEcCtD
Dihydroergotamine—Rash—Lamivudine—acquired immunodeficiency syndrome	0.000169	0.000561	CcSEcCtD
Dihydroergotamine—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	0.000169	0.00056	CcSEcCtD
Dihydroergotamine—Headache—Lamivudine—acquired immunodeficiency syndrome	0.000168	0.000557	CcSEcCtD
Dihydroergotamine—Nausea—Saquinavir—acquired immunodeficiency syndrome	0.000167	0.000554	CcSEcCtD
Dihydroergotamine—Nausea—Lamivudine—acquired immunodeficiency syndrome	0.000159	0.000528	CcSEcCtD
Dihydroergotamine—ADRA2A—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	8.83e-05	0.00322	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	8.8e-05	0.00321	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	8.73e-05	0.00318	CbGpPWpGaD
Dihydroergotamine—HTR1A—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	8.66e-05	0.00316	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	8.61e-05	0.00314	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	8.49e-05	0.0031	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	8.49e-05	0.0031	CbGpPWpGaD
Dihydroergotamine—HTR2B—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	8.49e-05	0.00309	CbGpPWpGaD
Dihydroergotamine—HTR6—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	8.38e-05	0.00305	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	8.36e-05	0.00305	CbGpPWpGaD
Dihydroergotamine—HTR1D—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	8.31e-05	0.00303	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	8.3e-05	0.00303	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	8.3e-05	0.00303	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	8.22e-05	0.003	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	8.16e-05	0.00298	CbGpPWpGaD
Dihydroergotamine—HTR1B—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	8.14e-05	0.00297	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	8.1e-05	0.00295	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	8.09e-05	0.00295	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	7.99e-05	0.00291	CbGpPWpGaD
Dihydroergotamine—HTR1A—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	7.8e-05	0.00284	CbGpPWpGaD
Dihydroergotamine—HTR2B—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	7.65e-05	0.00279	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	7.56e-05	0.00276	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	7.51e-05	0.00274	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	7.33e-05	0.00267	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	7.24e-05	0.00264	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	7.11e-05	0.00259	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	7.11e-05	0.00259	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	7.08e-05	0.00258	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Platelet activation, signaling and aggregation—CSF2—acquired immunodeficiency syndrome	7.04e-05	0.00257	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	7.03e-05	0.00256	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	6.89e-05	0.00251	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	6.89e-05	0.00251	CbGpPWpGaD
Dihydroergotamine—HTR1A—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	6.88e-05	0.00251	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	6.88e-05	0.00251	CbGpPWpGaD
Dihydroergotamine—ADRA2A—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	6.8e-05	0.00248	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	6.73e-05	0.00245	CbGpPWpGaD
Dihydroergotamine—ABCB1—Allograft Rejection—IFNG—acquired immunodeficiency syndrome	6.59e-05	0.0024	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	6.56e-05	0.00239	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	6.46e-05	0.00236	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	6.38e-05	0.00233	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	6.37e-05	0.00232	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	6.33e-05	0.00231	CbGpPWpGaD
Dihydroergotamine—HTR1A—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	6.2e-05	0.00226	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	6.2e-05	0.00226	CbGpPWpGaD
Dihydroergotamine—ADRA2A—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	6.13e-05	0.00223	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	6.09e-05	0.00222	CbGpPWpGaD
Dihydroergotamine—ABCB1—Allograft Rejection—IL2—acquired immunodeficiency syndrome	5.86e-05	0.00214	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	5.82e-05	0.00212	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	5.76e-05	0.0021	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	5.69e-05	0.00207	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	5.62e-05	0.00205	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	5.59e-05	0.00204	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	5.57e-05	0.00203	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	5.55e-05	0.00202	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—TAT—acquired immunodeficiency syndrome	5.5e-05	0.002	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	5.46e-05	0.00199	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	5.44e-05	0.00198	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	5.41e-05	0.00197	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	5.41e-05	0.00197	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	5.41e-05	0.00197	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	5.37e-05	0.00196	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	5.37e-05	0.00196	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	5.33e-05	0.00194	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	5.33e-05	0.00194	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	5.29e-05	0.00193	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	5.26e-05	0.00192	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	5.26e-05	0.00192	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	5.24e-05	0.00191	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	5.22e-05	0.0019	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	5.22e-05	0.0019	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	5.22e-05	0.0019	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	5.22e-05	0.0019	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	5.16e-05	0.00188	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	5.13e-05	0.00187	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	5.11e-05	0.00186	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	5.11e-05	0.00186	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	5.11e-05	0.00186	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	5.08e-05	0.00185	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	5.04e-05	0.00184	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	4.94e-05	0.0018	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	4.9e-05	0.00179	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	4.9e-05	0.00179	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	4.87e-05	0.00178	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	4.86e-05	0.00177	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	4.82e-05	0.00176	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	4.8e-05	0.00175	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	4.8e-05	0.00175	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	4.78e-05	0.00174	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	4.78e-05	0.00174	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	4.78e-05	0.00174	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	4.74e-05	0.00173	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	4.74e-05	0.00173	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	4.72e-05	0.00172	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	4.72e-05	0.00172	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—AGPS—acquired immunodeficiency syndrome	4.67e-05	0.0017	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	4.64e-05	0.00169	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	4.64e-05	0.00169	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	4.64e-05	0.00169	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—IFNA1—acquired immunodeficiency syndrome	4.64e-05	0.00169	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Platelet activation, signaling and aggregation—ALB—acquired immunodeficiency syndrome	4.59e-05	0.00167	CbGpPWpGaD
Dihydroergotamine—HTR1A—SIDS Susceptibility Pathways—TNF—acquired immunodeficiency syndrome	4.55e-05	0.00166	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	4.43e-05	0.00162	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	4.36e-05	0.00159	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	4.36e-05	0.00159	CbGpPWpGaD
Dihydroergotamine—ABCB1—Allograft Rejection—TNF—acquired immunodeficiency syndrome	4.27e-05	0.00156	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	4.16e-05	0.00152	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	4.14e-05	0.00151	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	4.12e-05	0.0015	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	4e-05	0.00146	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	3.98e-05	0.00145	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	3.98e-05	0.00145	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	3.97e-05	0.00145	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	3.94e-05	0.00144	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	3.91e-05	0.00143	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	3.89e-05	0.00142	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	3.89e-05	0.00142	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	3.89e-05	0.00142	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	3.83e-05	0.0014	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—TAT—acquired immunodeficiency syndrome	3.8e-05	0.00139	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	3.76e-05	0.00137	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Platelet activation, signaling and aggregation—IL2—acquired immunodeficiency syndrome	3.72e-05	0.00136	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	3.71e-05	0.00135	CbGpPWpGaD
Dihydroergotamine—HTR1A—SIDS Susceptibility Pathways—IL6—acquired immunodeficiency syndrome	3.68e-05	0.00134	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	3.65e-05	0.00133	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	3.63e-05	0.00132	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—CSF2—acquired immunodeficiency syndrome	3.63e-05	0.00132	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	3.61e-05	0.00131	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	3.6e-05	0.00131	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	3.6e-05	0.00131	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	3.6e-05	0.00131	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	3.58e-05	0.00131	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	3.58e-05	0.0013	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	3.55e-05	0.0013	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	3.54e-05	0.00129	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	3.54e-05	0.00129	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	3.53e-05	0.00129	CbGpPWpGaD
Dihydroergotamine—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	3.51e-05	0.00128	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	3.5e-05	0.00128	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	3.48e-05	0.00127	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	3.32e-05	0.00121	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	3.32e-05	0.00121	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	3.29e-05	0.0012	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	3.29e-05	0.0012	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	3.27e-05	0.00119	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	3.27e-05	0.00119	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	3.27e-05	0.00119	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	3.25e-05	0.00119	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	3.25e-05	0.00118	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—AGPS—acquired immunodeficiency syndrome	3.23e-05	0.00118	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	3.22e-05	0.00118	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	3.18e-05	0.00116	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	3.12e-05	0.00114	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	3.12e-05	0.00114	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	3.06e-05	0.00112	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	3.06e-05	0.00112	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	3.03e-05	0.0011	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	3e-05	0.00109	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	2.99e-05	0.00109	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.98e-05	0.00109	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	2.96e-05	0.00108	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	2.96e-05	0.00108	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	2.92e-05	0.00106	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.92e-05	0.00106	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	2.83e-05	0.00103	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.82e-05	0.00103	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.82e-05	0.00103	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.8e-05	0.00102	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.8e-05	0.00102	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	2.78e-05	0.00101	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	2.78e-05	0.00101	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.74e-05	0.001	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.74e-05	0.001	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.74e-05	0.000999	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	2.69e-05	0.000981	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	2.67e-05	0.000973	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	2.65e-05	0.000966	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.58e-05	0.000939	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.58e-05	0.000939	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.46e-05	0.000896	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	2.42e-05	0.000884	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—ALB—acquired immunodeficiency syndrome	2.36e-05	0.000862	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—TAT—acquired immunodeficiency syndrome	2.34e-05	0.000854	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	2.33e-05	0.000849	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	2.29e-05	0.000836	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.22e-05	0.00081	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.15e-05	0.000783	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.13e-05	0.000777	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.11e-05	0.000771	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	2.11e-05	0.000771	CbGpPWpGaD
Dihydroergotamine—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—acquired immunodeficiency syndrome	2.11e-05	0.000768	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.1e-05	0.000765	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	2.1e-05	0.000765	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.09e-05	0.000762	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.09e-05	0.000762	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.09e-05	0.000761	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	2.08e-05	0.000759	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	2.08e-05	0.000759	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	2.07e-05	0.000754	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.05e-05	0.000749	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	2.02e-05	0.000738	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—AGPS—acquired immunodeficiency syndrome	1.99e-05	0.000726	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.96e-05	0.000714	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.93e-05	0.000705	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.93e-05	0.000704	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.93e-05	0.000704	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.92e-05	0.0007	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—IL2—acquired immunodeficiency syndrome	1.92e-05	0.000699	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.9e-05	0.000694	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.9e-05	0.000693	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.89e-05	0.00069	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.88e-05	0.000685	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.88e-05	0.000684	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.84e-05	0.00067	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.77e-05	0.000644	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.75e-05	0.000637	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.73e-05	0.00063	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.64e-05	0.000599	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.64e-05	0.000599	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.59e-05	0.000579	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.56e-05	0.000571	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.54e-05	0.000562	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.43e-05	0.000522	CbGpPWpGaD
Dihydroergotamine—ABCB1—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	1.42e-05	0.000516	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.4e-05	0.00051	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.25e-05	0.000455	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.23e-05	0.000449	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.21e-05	0.000442	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.12e-05	0.00041	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.12e-05	0.000407	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.11e-05	0.000405	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.11e-05	0.000404	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.1e-05	0.000402	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.1e-05	0.000401	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.09e-05	0.000396	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.08e-05	0.000394	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.02e-05	0.000372	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.01e-05	0.00037	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—ALB—acquired immunodeficiency syndrome	9.59e-06	0.00035	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—IL2—acquired immunodeficiency syndrome	8.27e-06	0.000302	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	8.23e-06	0.0003	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—ALB—acquired immunodeficiency syndrome	6.63e-06	0.000242	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—IL6—acquired immunodeficiency syndrome	6.57e-06	0.000239	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—IL6—acquired immunodeficiency syndrome	6.52e-06	0.000238	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—IL2—acquired immunodeficiency syndrome	6.5e-06	0.000237	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	6.47e-06	0.000236	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—IL6—acquired immunodeficiency syndrome	6.38e-06	0.000233	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—IL6—acquired immunodeficiency syndrome	5.99e-06	0.000219	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—IL6—acquired immunodeficiency syndrome	4.86e-06	0.000177	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—ALB—acquired immunodeficiency syndrome	4.08e-06	0.000149	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.82e-06	0.000139	CbGpPWpGaD
